Loading patent…
AssigneeSmithKline Beecham Biologicals s.a.
InventorsMartin Friede, Sean Mason, William G. Turnell, Carlota Vinals y de Bassols, Marcelle Paulette Van Mechelen
Estimating the term…
The present invention relates to the provision of novel medicaments for the treatment, prevention or amelioration of allergic disease. In particular, the novel medicaments are epitopes or mimotopes derived from the Cε3 or Cε4 domains of IgE. These novel regions may be the target for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to methods for production of the medicaments, pharmaceutical compositions containing them and their use in medicine. Also forming an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.
A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P5 (SEQ ID No. 1), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P6 (SEQ ID No. 2), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the region spanning Cε3 and Cε4 domains of IgE, wherein the peptide is P7 (SEQ ID No. 3), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is P8 (SEQ ID No. 4), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is P9 (SEQ ID No. 5), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P200 (SEQ ID No. 6), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is P210 (SEQ ID No. 7), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε3 domain of IgE, wherein the peptide is 2-90N (SEQ ID No. 82), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is 3-90N (SEQ ID No. 83), or mimotope thereof.
A peptide comprising an isolated surface exposed epitope of the Cε4 domain of IgE, wherein the peptide is 4-90N (SEQ ID No. 84), or mimotope thereof.
Use of P14/23, P14/31 or P14/33;
A peptide which is capable of being recognised by P14/23, P14/31 or P14/33;
Dependencies are inferred from the claim text.